Protein Disulfide Isomerase Endoplasmic Reticulum Protein 57 (ERp57) is Protective Against ALS-Associated Mutant TDP-43 in Neuronal Cells
-
Published:2024-06-11
Issue:1
Volume:26
Page:
-
ISSN:1559-1174
-
Container-title:NeuroMolecular Medicine
-
language:en
-
Short-container-title:Neuromol Med
Author:
Parakh Sonam,Perri Emma R.,Vidal Marta,Takalloo Zeinab,Jagaraj Cyril J.,Mehta Prachi,Yang Shu,Thomas Colleen J.,Blair Ian P.,Hong Yuning,Atkin Julie D.
Abstract
AbstractAmyotrophic Lateral Sclerosis (ALS) is a severe neurodegenerative disease affecting motor neurons. Pathological forms of Tar-DNA binding protein-43 (TDP-43), involving its mislocalisation to the cytoplasm and the formation of misfolded inclusions, are present in almost all ALS cases (97%), and ~ 50% cases of the related condition, frontotemporal dementia (FTD), highlighting its importance in neurodegeneration. Previous studies have shown that endoplasmic reticulum protein 57 (ERp57), a member of the protein disulphide isomerase (PDI) family of redox chaperones, is protective against ALS-linked mutant superoxide dismutase (SOD1) in neuronal cells and transgenic SOD1G93A mouse models. However, it remains unclear whether ERp57 is protective against pathological TDP-43 in ALS. Here, we demonstrate that ERp57 is protective against key features of TDP-43 pathology in neuronal cells. ERp57 inhibited the mislocalisation of TDP-43M337V from the nucleus to the cytoplasm. In addition, ERp57 inhibited the number of inclusions formed by ALS-associated variant TDP-43M337V and reduced the size of these inclusions. ERp57 was also protective against ER stress and induction of apoptosis. Furthermore, ERp57 modulated the steady-state expression levels of TDP-43. This study therefore demonstrates a novel mechanism of action of ERp57 in ALS. It also implies that ERp57 may have potential as a novel therapeutic target to prevent the TDP-43 pathology associated with neurodegeneration.
Funder
National Health and Medical Research Council of Australia Motor Neuron Disease Research Australia The Dementia Australia Research Foundation Macquarie University
Publisher
Springer Science and Business Media LLC
Reference47 articles.
1. Acewicz, A., Stępień, T., Felczak, P., Tarka, S., & Wierzba-Bobrowicz, T. (2022). Incidence and morphology of secondary TDP-43 proteinopathies: Part 1. Folia Neuropathologica, 60(3), 267–276. https://doi.org/10.5114/fn.2022.120314 2. Bargsted, L., Hetz, C., & Matus, S. (2016). ERp57 in neurodegeneration and regeneration. Neural Regeneration Research, 11(2), 232–233. https://doi.org/10.4103/1673-5374.177722 3. Barmada, S. J., Serio, A., Arjun, A., Bilican, B., Daub, A., Ando, D. M., Tsvetkov, A., Pleiss, M., Li, X., Peisach, D., Shaw, C., Chandran, S., & Finkbeiner, S. (2014). Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nature Chemical Biology, 10(8), 677–685. https://doi.org/10.1038/nchembio.1563 4. Barmada, S. J., Skibinski, G., Korb, E., Rao, E. J., Wu, J. Y., & Finkbeiner, S. (2010). Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. Journal of Neuroscience, 30(2), 639–649. https://doi.org/10.1523/jneurosci.4988-09.2010 5. Bilches Medinas, D., Malik, S., Yildiz-Bölükbasi, E., Borgonovo, J., Saaranen, M. J., Urra, H., Pulgar, E., Afzal, M., Contreras, D., Wright, M. T., Bodaleo, F., Quiroz, G., Rozas, P., Mumtaz, S., Díaz, R., Rozas, C., Cabral-Miranda, F., Piña, R., Valenzuela, V., … Tolun, A. (2022). Mutation in protein disulfide isomerase A3 causes neurodevelopmental defects by disturbing endoplasmic reticulum proteostasis. EMBO Journal, 41(2), e105531. https://doi.org/10.15252/embj.2020105531
|
|